Oncoclínicas (B3: ONCO3) net income
Oncoclínicas reported a net loss of BRL 3,624m for fiscal 2025; in fiscal 2024 it reported a net loss of BRL 646.2m.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin |
|---|---|---|---|
| 2025 | −BRL 3,624m | — | −63.1% |
| 2024 | −BRL 646.2m | −389.0% | −10.4% |
| 2023 | BRL 223.6m | +383.4% | 4.1% |
| 2022 | BRL 46.3m | — | 1.1% |
| 2021 | −BRL 46.9m | — | −1.7% |
| 2020 | −BRL 159.6m | — | −7.8% |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of Brazilian reais, except per-share amounts.
Questions about the net income of Oncoclínicas
- How much did Oncoclínicas earn in fiscal 2025?
- Oncoclínicas reported a net loss of BRL 3,624m for fiscal 2025. In fiscal 2024 it reported a net loss of BRL 646.2m.
- What was the most profitable year for Oncoclínicas?
- Of its last 6 fiscal years, fiscal 2023, with BRL 223.6m.
- Where do the figures for Oncoclínicas come from?
- From the annual financial statements (DFP) that Oncoclínicas files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual financial statements (DFP) that Oncoclínicas files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Oncoclínicas: the Oncoclínicas page · annual accounts · revenue · dividends paid.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.